Healthcare / Diagnostics & ResearchNSE
$464.00
+1.85 (+0.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 22%
FCF escenarios
weak_data · normalized FCF $145.6M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
54/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$20.8B
P/E
27.0x
↑EV/EBITDA
13.9x
↑ROE
17.0%
↑Gross Margin
80.2%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+8.9%
FCF CAGR
+7.5%
FCF margin
11.6%
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.07B · net income $775.1M · FCF $473.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.07B | $4.07B | $3.44B | $2.89B | $3.15B |
| Net Income | $775.1M | $775.1M | $673.4M | $410.1M | $481.7M |
| EBITDA | $1.49B | $1.49B | $1.27B | $982.2M | $966.4M |
| EPS | 17.20 | 17.20 | 14.93 | 9.12 | 10.68 |
| Gross Margin | 80.2% | 80.2% | 79.2% | 80.0% | 76.6% |
| Operating Margin | 24.0% | 24.0% | 25.2% | 22.3% | 22.1% |
| Net Margin | 19.0% | 19.0% | 19.6% | 14.2% | 15.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.06 | 0.05 |
| Current Ratio | 3.43 | 3.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $473.4M | $473.4M | $145.6M | $-156.8M | $381.3M |
| Returns | |||||
| ROE | 17.0% | 17.0% | 17.8% | 13.1% | 17.1% |
| Valuation | |||||
| P/E | 26.99 | 26.99 | 30.96 | 25.94 | 15.99 |
| EV/EBITDA | 13.91 | 13.91 | 16.41 | 10.89 | 7.81 |
| P/B | 4.58 | 4.58 | 5.50 | 3.39 | 2.73 |
| Growth & Yield | |||||
| Revenue Growth | 18.4% | 18.4% | 19.2% | -8.4% | — |
| EPS Growth | 15.2% | 15.2% | 63.7% | -14.6% | — |
| Dividend Yield | 0.4% | 0.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
33.8%
EPS terminal req.
$41.17
Spread vs growth
-18.6%
5Y implied EPS CAGR
23.7%
EPS terminal req.
$49.82
Spread vs growth
-8.5%
10Y implied EPS CAGR
16.6%
EPS terminal req.
$80.23
Spread vs growth
-1.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.1%
Start / end P/E
32.9x → 27.0x
EPS bridge
14.93 → 17.20
Residual
-2.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.